Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
Naoko IidaMitsuho ImaiWataru OkamotoTakeshi KatoTaito EsakiKen KatoYoshito KomatsuSatoshi YukiToshiki MasuishiTomohiro NishinaHiromichi EbiHiroya TaniguchiNorio NonomuraYu SunakawaManabu ShiozawaKentaro YamazakiShogen BokuHideaki BandoYuichi ShiraishiMaki KobayashiHiroki GotoAkihiro SatoSatoshi FujiiTakayuki YoshinoYoshiaki NakamuraPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
This study highlighted the importance of ERBB2 genomic status when evaluating the efficacy of HER2-targeted therapies in ERBB2-amplified mCRC. The identification of a novel splicing-associated variant may provide insights into potential mechanisms of treatment resistance. Furthermore, we demonstrated the utility of ctDNA to follow the acquired genomic status of mCRC tumors.